<SEC-DOCUMENT>0001193125-14-189237.txt : 20140508
<SEC-HEADER>0001193125-14-189237.hdr.sgml : 20140508
<ACCEPTANCE-DATETIME>20140508111323
ACCESSION NUMBER:		0001193125-14-189237
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140508
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140508
DATE AS OF CHANGE:		20140508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		14823568

	BUSINESS ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d722572d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): May&nbsp;8, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GlycoMimetics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36177</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1686563</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>401 Professional Drive, Suite 250 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Gaithersburg, MD 20879 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(240) 243-1201 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02 Results of Operations and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;8, 2014, GlycoMimetics, Inc. (the &#147;<B><I>Registrant</I></B>&#148; or the &#147;<B><I>Company</I></B>&#148;) issued a press
release announcing its financial results for the quarter ended March&nbsp;31, 2014. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with General Instruction B.2. of Form 8-K, the information in this Item&nbsp;2.02, and Exhibit 99.1 hereto, shall not be deemed
&#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by
reference in any of the Registrant&#146;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set
forth by specific reference in such a filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May 8, 2014, &#147;GlycoMimetics Reports First Quarter 2014 Results.&#148;</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>GLYCOMIMETICS, INC.</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rachel K. King</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;8, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rachel K. King</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive
Officer</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May 8, 2014, &#147;GlycoMimetics Reports First Quarter 2014 Results.&#148;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d722572dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g722572ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLYCOMIMETICS REPORTS FIRST QUARTER 2014 RESULTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GAITHERSBURG, MD, May&nbsp;8, 2014 </B>&#150; GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended
March&nbsp;31, 2014. As of March&nbsp;31, 2014, GlycoMimetics had cash and cash equivalents of $57.0 million, which reflects the company&#146;s January 2014 initial public offering (IPO) in which it sold 8,050,000 shares of its common stock at $8.00
per share, including the underwriters&#146; exercise in full of their option to purchase 1,050,000 additional shares of common stock. The aggregate net proceeds to GlycoMimetics from the IPO, after underwriting discounts and commissions and offering
expenses, were $57.3 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics reported no revenue for the quarter ended March&nbsp;31, 2014. This compares to $3.8 million for the quarter
ended March&nbsp;31, 2013. The company received an upfront payment of $22.5 million from Pfizer in 2011 under a collaboration agreement that was recognized as revenue through March&nbsp;31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of its agreement with Pfizer, GlycoMimetics is entitled to receive a milestone payment of $35.0 million upon the initiation of dosing of the
first patient with the drug candidate rivipansel (GMI-1070) in a Phase 3 trial, which Pfizer will conduct. Under the agreement, GlycoMimetics is also entitled to receive a $15.0 million advance against this milestone payment if the first patient was
not dosed by April 2014. The company currently expects to receive the $15.0 million advance payment from Pfizer in the second quarter of 2014 and the initiation of the Phase 3 clinical trial in the second half of 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#146;s research and development expenses increased to $3.9 million for the quarter ended March&nbsp;31, 2014 as compared to $2.7 million for the
first quarter of 2013. This increase reflects spending for advanced pre-clinical testing and manufacturing of the company&#146;s drug candidate GMI-1271 for the treatment of acute myeloid leukemia (AML) and other cancers, for which clinical testing
is expected to begin in the second quarter of this year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company&#146;s general and administrative expenses increased to $1.2 million for the quarter
ended March&nbsp;31, 2014 as compared to $0.6 million for the first quarter of 2013. The increase was primarily due to costs associated with the company&#146;s IPO and other costs associated with supporting public company operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;GlycoMimetics accomplished a great deal in the first quarter of 2014, highlighted by our IPO in January,&#148; said Rachel King, CEO of GlycoMimetics.
&#147;We have continued to advance both our rivipansel program in sickle cell disease, which is partnered with Pfizer, and our GMI-1271 program, which we plan to develop for blood cancers and which we expect to enter clinical trials before the end
of the second quarter.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Select Recent Corporate Highlights: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In January 2014, GlycoMimetics closed its IPO and announced the full exercise of the underwriters&#146; option to purchase additional shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In April 2014, findings from research studies of GlycoMimetics&#146; E-Selectin antagonist (GMI-1271) were shared via three posters at the&nbsp;American Association for Cancer Research&nbsp;(AACR) Annual Meeting 2014.
The posters highlighted GMI-1271&#146;s potential as a treatment for solid tumors (for example, for breast cancer metastasis) as well as for its use to potentially improve chemotherapy treatment. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Also in April 2014, data was presented at the 8th Annual&nbsp;Sickle Cell Disease Research&nbsp;and Educational Symposium&nbsp;and 37th National Sickle Cell Disease Scientific Meeting on the use of rivipansel in sickle
cell patients already on hydroxyurea, a common drug treatment for sickle cell disease. In the study for which data was presented, patients on hydroxyurea appeared to benefit similarly from the addition of rivipansel to their standard treatment
regimen as compared to those patients receiving rivipansel but not being treated with hydroxyurea. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About GlycoMimetics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs
resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of
carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements regarding GlycoMimetics&#146; expectations regarding potential payments under its collaboration with Pfizer, planned activities with respect to the clinical development of GMI-1271, and other matters. Actual results may
differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the company&#146;s
Annual Report on Form 10-K for the year ended December&nbsp;31, 2013 filed with the U.S. Securities and Exchange Commission on March&nbsp;31, 2014, and other filings GlycoMimetics makes with the SEC from time to time, including those factors
discussed under the caption &#147;Risk Factors&#148; in such filings. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GlycoMimetics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(A Development Stage Enterprise) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Statements of Operations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands except per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three months ended March&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(Unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost and Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income and comprehensive (loss) income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income per share &#150; basic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income per share &#150; diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares &#150; basic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,232,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">930,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares &#150; diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,232,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,128,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GlycoMimetics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(A Development Stage Enterprise) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Balance Sheet Data </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands)
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">March&nbsp;31,&nbsp;2014<BR>(Unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g722572ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722572ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3P%Y`P$1``(1`0,1`?_$`+H``0`!!0$!`0$`````
M```````(!08'"0H#`@$$`0$``04!`0```````````````0(#!@<(!000```&
M`@(!`P$%!`8&"P$```$"`P0%!@`'$0@)(1(3%#%!(A4*46$C%H&T-3AX.3(S
M%W>W&)'!0R1$)3>'*$D:.A$``0($!`,%!00'!P4!`````0`"$0,$!2$Q$@9!
M40=A<8$B$_"1H;$RP=%"%.%2<B,S<Q7Q8H*BLC0(PD-C)#46_]H`#`,!``(1
M`Q$`/P#OXPB81,(J!:+56:3`REIN-@AJM6H5HL^EYZ?DFD3$1K-`AE%G#U^^
M50;-TB$*(\F,&$6@:P_J;_%W`=EVO7T-B6*7K9CFC)+L!$POU6G8NQ"Z,@E'
MFEP6"0>0YD@!0\LB@9BF/)1-R`Y$1&'M'@/'[%<](Z2[CAASCQ\#@5OGH.PZ
M)M2J1%ZUM;ZY>J;/M$7T-9JK+LIN&D6JZ9%DU&S]@LL@?E-0!$O(&+SP(`.3
MV\%006G2<PKQPH3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7X(@`"(B```"(B(
M\``!]HB/W`&$6B3R0?J`.FG0A:2US7)(_9+LB45&3#3NK'Z$DVB)CW$22:7R
MWLR2$;6U`74`IVB)'DF`_P#A@#UP<&Q&)X#GP5;&:\3@SGGX=I[%H3NW7SR;
M>6J&3[%>5S?[+QX>/\%TY&"TR1=S6)>T,_J#*Q<?$:VD'1)NP3\HD@F5%S/'
M5<+K`19C'&`WMRKTWN=Z>?"`&),<,,<<@<3QP5S6R420,0!$DB`A`DQQ$,3R
MA#/BI*0NGO&!!:</H2O>+^QW'J"]8D-8^P%B=MFG<B;G"-A(CLZ%J3N-86Y.
M#:I#\QF97\<].KZ)P)PY*;.)?3G=L^U&Z-I'"GA'0<)A$/J#/K/N#NR"U_-Z
MG[,DWEME-:P51_%_V6G@TS?I#N9)@,071P49Z5T[[Y>.Q*1[2>#WM`IW+ZE)
M2SF2OO5VP.1>W*J*)F^KE:W<M4N5H]T:?BVR94UU(].)L0J<>]D)0]<*?*F2
M293VELQOX7"!!R[#&.8@.4%GDF;)FRP\$&6X$APR(X'#,'A#!;K?'1^HIZI=
MOY&/T[O]LMU$[0MUS0\MK[9:ZL93IB>;*`U<M*U<9="-39OSN_P!'2J;)V54
M?C3^80]PVN)X'[H1]T4]-Q/EQ'"&/L>S/C!=#B2J2Z::R*A%D52%4252.51-
M1,X`8ATSD$2G(8H\@(#P(85"^\(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%#?O-WMZ]
M^/'1KS?O8ZQ2$)4?SEM5:_'0L6XF)^VW&0CI24BZO!,D`*D:1?,H9RH!EE$D
M2)HF$3<\`+#BJF-<]P:W,KDPN?<KS"^=1S.5_JG7S]!.@+===O<MYVJ96K+V
M;J(E_P"_/9N].@BY"=(#4BICL(/Z*..D;XW+@QB";&EQ!:Z`:8XYF'##MY<C
MBKHT2P'")F@_/CX<.?8LC]3^M_2#H:X]G2C6<=W7[31SMXA:N\78*.<):?H%
M@#XTY#_9C!A\3JT/FJRBJ8!$F;BJF)3GE')0,3,VVQL.^[IF>K1RS*HHXSID
M0T<],<7?X<#S6![OZB[=VA*+*Z;ZE?"#9$LQ>?V^#!',G'D%))Y4K!>;BAM+
M?5^G][[60*L6.L]R39MX"G(.%3JJ1FMZ)&HMJK1HTI#%2.+-L1P[*D0[A117
MDX])[6Z=6#;+6S0S\S<AG-F`&!_N-R;#@?JYDKE7>'5'<>[8TQ?^5M,3^YED
M^;^8[-Y[/I'`!7]R///(\_MY]<SY:V6/W%&<1-P3VEJJW6/2NXFR";9#9>O5
MD&,C(LT507)#W&$<)K5Z]5XZH<G8RC=PB(C[@`#<#F%;GV'8-TL+ZJ7Z5PA`
M3F`!P[QDX=X)'""S[:/4?<>T'B733/7MD<9$PDL[V&.IA_9(!_$"%@WM7J#J
M-WC:EB/(YI^.TGNI?Z:*IWD&ZUPSIM"2LF!#LX0-QTM%.0D($Y5#)BH=W^81
MYU#',D=@F4..;MU].K]MIQFN9^8M@(A-9'B<G-&+>9_",R0NJ-G]3]N[J:V3
M3S/R]T#?-)FD`XX'TW8!X,880=$C`YK!E1W/YB_!)'PK^:<,_)/XV#)(&JEZ
MJ\PI8PJ]/(LD1NYA+$Q5G9ZBE!O[B(-USR<&7@YQ`H_9KXQ)PQ!^'Z/8<ELK
MR.,'@AP'Q[OGSA@!QZH/';Y+>M'DSU+);1Z\3$Q]14WT?!['H]FC%XRS4*R2
M$>610BI/DIF+]%RW]QV[ENH<BJ0`8Q4Q'V!)&$>V']JM/89;M+EL%R%0F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3"+E,_5[ASXZ-(@(<_\`S*US_P!`ZTV\`_T<9#OH=X?Z
M@K\CZ_=\PK^[:MU+MM?KWU^FG\DCHJF]%])[<9:A@G05V@2]_L5ZOM8=S5GA
M(5-F2?3:1-=;E;-%3@T34%0YDU!4'-Q](]N6B_7*KG7:5ZWY5LMS&DG3%Q>#
MJ'XLA`1P6D.M6Z;YMRUTDJS3A)-9,FLF.`B\!C6$:'?A^H@GB,,%3&C5JP:-
MF#!JV8L62)&[-BR02:,VC=,.$T&K5N1-!NB0/L*0H%#]F=12Y;)3!*E-#9;1
M``"``[`%R%,F3)TPS9KG/FN,22223VDXE>^5*A,(F$7PHFFLDJ@LFFL@NF=%
M=!8A%45T5"B51%9)0#)JI*%'@Q3`("'H(9#FM>TL>`6$0(.((Y$<0JFN<QP>
MPEKVF((,"#S!&(*OCHS&AK;N+1=7TU](Q6I-ST/;TAL/42KD)+6DM+U5I5!A
MIEC5)%-TR@WI$YEPDL1I\35=(Q0,ER7D>;>L.V;-:/RUSMLH2:BH>\/#3Y#I
MTD$-X'$Q(S75?1'=5]OLNKMMWGF?(I&2O3+A%XU%\07YN`TB$<1S4+OTCZ22
M,5Y+4D4R)(H]I6Z**21"IHI(I-9Y-))%,H`5-)(A0*4H````<!Z9HL$F,>8^
M(^/>N@9Q.H`\`._Q/%=CAC`4!,80*4H"8QC"``4`#D1$1]```R594!-V^4[Q
MV=<[$XJ&Z.XNAZ);&:P-W=9E+W$JSK53V"<WU$8Q5=.D2)E#\9C%`"B(`/`B
M`8B!F0("*D-<8P&7VY+,^@NY'53M,S7?==.P6I]RMVP`9Q_(-SAYYP@`@(_Q
MF;5R+M/V\?BY('M'T'C'WP0M(S&2OS=V]-2=;];SNWMXWJ"UMK6LGCR3UPLC
M@6D/&&E'[>,CP=+E(H)!=/W2:1/3U,<`R0-1@,T`),!FK[JUG@;M6:]<JK*-
M9NL6R#BK)79ED<5&<M!S;%"2BI)HH(`)VSYBY35(/`<E,&0H5>PB81,(F$3"
M)A$PBLP-BT0UB&I%ML`-F*X%H,$$DV_-`=`4#"W%I[_E^4"CS[>.<]4V.\"A
M_J1IIW]/TZO4TG1#GJR@O(_K]D-?_2A52/ZEJT^GK&N/+3G'L5YYY2]=6=![
M"H]EDW,+7[9`S,LS(JHZCHZ2;.G:":"A$ECJ(I',<I$E%2E,/V`)@SU*NR7>
M@IVU=;33I5,\@!SFD-)(B($\P"O)HK]9;C4NI*"JD3JI@)+6/#G``@$D#D2`
MJ%;]RZSH<]%UFV6V,AIN8^(63%R<_P`@D75^%%582$,5NDJK^$ICB`".?7;=
MKW^\44VX6VFF3:25'4X#D(D#F0,3!?%==W;<LE=*MMTJY4FMG0TM<<<3`$\`
M"<`2LF%,4Y2G(8#%,4#%,40$IBF#D#`(>@@(#G@+(\\1DOK")A$PB81,(J)8
M;)`5*)<SMFEV$%#,_C^JDY-P1JS0^4Y4T_E74$"$]ZA@`.?M$<^NAH*VYU+:
M.WRGSJIT8,8(N,,3`#L7Q7"XT-JI75URFLD4;(:GO(:T1P$2>U4!+9M`<5%Y
M?6MMA'5.CRJB[L35\DO&)"B<B:A!<)B8HJ_*H4H%#U$Q@`/4<^UU@O3+FVS3
M*:<VZ/A"46D/,<<CP@"8\@OA9N.Q3+4^^2JJ2^T2XZIK7`L$,#B.,2!#F8+V
MHVPZ9LJ(/.4F>93\:DX,T<+,SB)FSHA2G%!RD<"JH*BF<#`!@#DH@(91=['=
M;#4BDNTE\F>6Z@'<1S!R(CAWJNRW^T;BI#6V:>R?3AVDEO!PX$9@PQQX*],\
MI>PF$3")A$PB818N<[MU$SVO&:*=['I[?<DS7WMKB=9*SC(ESD:U&@0S^<:0
M(J@^6C&8*%%14I!(7D.1PF?@LHX1,(F$3")A$PB81<IOZO;_`"Z-(_XR]<?\
M--O?N'(=_#=X?ZA[9CO5^G^OVY^'MP.2R-V(_O::H]1_RS^NGI]W_JUMKUY_
M;F_^A?\`O+I_*D_ZIG9]JYO_`.0P_P#0M1@/X]1CQ^B4J5G1"Y@3")A$PB81
M9'ZI?W^>N?\`NZ[`_P!1U_FBNN7_`,Z@_FS/DQ=&?\>O]Y=/Y<CYS%"#]))_
M9WDR_P`52?[Q_P!1/_:/V#_U9S:WCSB/E\.[@NH9N8Y0'8/`9CQSS4L/,7V3
M[*=CNUND?#5TCO3G5VP-TUUSL#LUN&/,[3?:ZTL*#Q1..8/XTH/XQU+L8QXX
M4407;N3_``HMR&+]1[@GL&<1CP''XB,%,L`-+SEB,LC\H'+FIJ]7?`MXS^LM
M.:0@]>JSNFYN&8!;MG;O2/L"SVR56.5P^DUF4NHK7H@5G0")"LVB1RI\`=10
MWN.8(-C#C#/'+VQA"/%4NFO=A'#[.7,^,>*C3VX_3L];+E(M=U]!IZ9Z&]KZ
MQ)-)BJ7_`%G-6)"B/W:#DBJ[6R5!-^L+=LLD4``(X[=N8"^Q9NL4X\1"/OBI
M$UT23Q]H=W9DJ[YXH"]U;P?;;K>T+HUV/L2#@]+1=SOC*#3K36VV%GL"I(R4
M\E`I.7B46$BX(*@I%4$H"(B`%`?:%QL-8AS25#U!#)2+TKY`=.=?VWC%Z>;-
M@;]"6KM-U<ULZU3LTT=7@U&\L%8UE"+2%&E9]Q9F\]'VU5--O\"(1BC=8[YN
M0JWO.)2T@1P&:I+2YSH</;^U;<I:5CH*+DIN8>MXV(AX]Y*RDB[4!)JPCH]N
MH[?/7*IOPIMVK9$QSF'T`I1'(5!P$5"#I+Y"--]Z],7CL'K6O7ZC:@I5XNE*
M)=MK-*M7(BTDH3E=M8;=6UXBV6$IZ:B*'O3>O/I!43,!@)P!O:X1X04N!;]7
M**UT6C]0AI2QW.SU'IYU-[B=YX^FR"T=8-D]?M5KRNK4G3-5,'R$=:'*XN7Z
MR2!5A2Y:))N3D(")SE4`X1$<,<OC'[O>J_3(Q<8`C#M/+OYQR4HNDGF/ZJ]U
M=B2NB6\9M'KMV7@VRKN3Z[=D:@.N=EJMV_'U+B%9*O'K&93(7^(")%B/?@_B
M&;D+SQ.'Q/PX]V*&4X`D0+1",.U9L[Z^2?JSXYJ'%W#L);'WY]:UE&6O-54M
MBE8MH['DDC$3,SJ=9%TS*JF150I#.72S9H10P$%7WB!188]BI#'.Q`PY\/>M
M7L;^H^T]5Y2&D.RO1WOEU4U%9I>/C(/>.WM)O8[7Z"<F=J1H_GW95TEFC<Y5
MCJ"#`)-04R@)2G]WX9=I'/",<,,.Z.?Z<E7Z1CI!!</NCAS^?8NA*FW:H;$J
M-?OU%LD-;:5:X=G8*W:8&0;R4'-PL@@5RSDXZ0;'.W<-'"!@,!RFX_;P(#@`
MG`8Q5DD`1.2T#6+8KU#>DQLUBJ=)XVV`YG$E2^AO8T?_``'X_$8!`[9$0#U$
M!`<[>H+%)=L^5M^<(RC1"61WMC\RN!;AN&<W>\[<LDPG-KS,![&N@<N8"W8;
M9VDSJ^B[!LJ.7*G]75$7<`IR53_S&P-T4(<IO:/!A3=/2"<`^SVC^S.3-N;>
MFW'=\BP3Q&%26S!EY99)F0_PM,/!=D[GW-*MFRJC<=.Z$:4.E'`^>:`)?^9P
MCXK4]TNL1X7L%6DS'`!LK.9@EC&$?QBY;&D_;S]XF6C@XY^T?W\9TEU7H6U6
MRI[N%.^7,'@='R>N6^CMP=1[\IVQQJ63)9\1K^;%)CMY":C6W;1%;E(7QE-2
MS2&35;UZ(B)&,?M"RZ;)D07CZ;C'$:L58W"IBHN`]GJ`<^F8#TQJ]RC:=:RU
M,HGTLISS&8][7M<6:G>5LMX<",@7-Q[%L7JO1;5=O*A?=WUS*N<R6")4N6YC
MVB8&M\SIC"PQP)#78=JE+M3LIKS1$U7Z;98VSK'>Q3=9HZB6<>Z9-6**@,2"
M[5=2C-Q[DP3Y-[$S^G[_`$S7FW=AWO>%)/NE!,IP&3"'![G!Q<1J\H#'#'M(
M6S-S=1+!LFMD6>XRZDN?*!:YC6N:UH.GS%SVG"&,`5B64\@>HV4T:/90=NEH
MU-;X5)MNUCT6Z@>\"_.T:N'Q'*S<"CSR<$C^G'M^_,DI^BNYYU&)\V;2RJ@B
M(EN<XD=CB&D`]T1VK%ZKKOM.16FGDR:N;3`P,UK6@'M:US@XM[])[%=5^[NZ
M;IR4<$0XD;L[DF3=^5&`22(BR0<E*HF21<OE&_T[KV&]4BD4.00X-[1SSK+T
MEW3=73/S+64DJ6\MC,)BXC`Z0T&(_O1`.8BO3OO6;:-H;+_*N?6S9C`\"5"#
M0[$:RXB#O[L"1D8+)VD^PU$WHTD#5GZ^.EX@J:DG`S":"3]!!4P$3>(BW7<(
MN61U?P^\#`(&X`Q2B(<X_NS9%YVA,8+CH?338Z)C"2TD?A,0"'0QA#N)62;.
MW[8]ZRIAMGJ2ZJ5`OE3``\`_B$"06QPB#W@*F[D[.:TTLN2+GG+R7LBB*;@*
M[!II.'R*"H_PEGJJZR#5F10OXBE,?Y#%X$"\"`Y]&UNG]_W6PU-$UDJA!AZL
MPD-)&8:`"70[!".$5\^[NH^W-G/%-7N?-N!;'TI8!<`<BXD@-![3&&("Q;1.
M]VIK=--H278SM.4>JD0:R,P1HM%"LJ<$TDG#EHN=5J*AC!^,R?QE^\P!ZYD-
MXZ/;EME*ZKIGR:IK!$M87!\!F0T@`]P,>06,V3K;M6ZU;:.J9/I'O,`Z8&ED
M3@`7-)(CS+8<RJ7WDVK78+78:Z<-Y-U+WU@64A7[)-HM$)MHF28&7%XY,\37
M**Q5RBE\:2A3!]HAGT](MN5U9>_ZZQTMM+1/T3&N+@\E[70TC3#"&,2(<E\O
M6G<]OHK!_P#GYC9CJNNEZY;FAIE@,>V.HZ@<8B$&F*CEI78NM['UQONEK6UM
MR)X>"E;G+R,,UC%$BLFLW!BQ_+S.9%$[EVC)*(G.DH1(ATBF#Y"B(#F<[KL=
M^H-]4>[+:ZF(FSF2&->7QU.ES-6J#3!I:'`$$D&!TE:]V=N#;UPZ>UVSKHVJ
M!E2'U$Q\MK"-(F2].B+P2X/TDM(:"`1J"E+T?CM?L-:V%_27=E>).K&I^=25
MI81\0JJZ:1[4"?2,8^5ET&S%%L8.1.L)Q/[A'TXS7G5N?>YU_DR;NVG:YL@>
MFR2YSP`7&.ISF,)<3R:`!#BMG=&:>PR-N3Y]E=4O:ZH/J/G-8PES6B&EK7O#
M6AL,W$QB<H+VV#WFU%2Y1U"Q:$S<WK-51!PY@TVB<0FND;V*)!(.W"9ES$-R
M'*:1R>G^EENR=(MSW:G;55!E4DEPB!,)UD'(Z6@PCVD'L55^ZU;3LU2ZCIA.
MK)[#`F4&^F",QK<1&'-K2.U75J7MYJG;,NWKC163K-B=B)&,98D6R!))4.1!
M&/>M7+ENJN8@<@104CF'T*!AXY^#<O3+<>VZ5U=-$NHH6_4^42=(YN:0"!VB
M(&9@O4VKU7VONFJ;;Y)F4]P=]+)H`UGDUS203V&!/`%5;=_9^@:.<LHB82D)
MZQOD#.BP<+],9=BU$!^!S*+.%DR-$W1@X3*`'4$`]WM`H@(_+M+I]>]W2W5-
M*9<FA8Z'J3(P<>(8`#J(XY#A&,5]6\^I-AV7,92U@F3[@]NKTY>F+1P+R2`T
M'AF>,(0*^M)]GM?;O=.HB#3DH6Q,VPO%(29*V(NX:D,4BKABLW763=)I&-^(
M/PG*'J)>,C=G3^][1EMJ:STYM"]VD3)<2`>`<"!I)\1P!4[-ZD6'>DQ]+0B9
M)KV-U&7,T@D9$M()#@..1&9"D?F"K8*81<R6Q./_`-3?7(?O_P"0S<?]2B/W
MX.8[C\^_[U='T']G_J4U]V^=+I#UWWMV+Z\[<6V55K]UVB:LZ<)_RS$2B&V;
M!<D8M:OT;3S"(LCZR6>VNB2Q!.BY8,&Z1"*'.L!"^[!PA'CEX>WWJGTW$`CC
M]G%8,KGZ@W44+L"A5OM%T\[E],M?[8GH^NZ[W3V"UBE6]>/)*3*D#-O9WY)`
MRM<5754YX(#PJ2(@LL*:?N,5A@`<3E\/O^W)5>D3])!/L</TP/8M\%EO%.IM
M.E]A6NSP=>HT#!KV69MLM)-64!&P#9J+U>7=RBZA&J3`C7\?R";VB40XYY#$
M."M@$F`S6A>7_4)ZFN=CG&/4'IAW<[K4:KR2\?.;BT?IUXYU@X,P4`)-*M34
M@J1],OVJ(&,1!5JT%<?;\8F*<#!.$8&/#+'/XJX)>>L@0]_N4S.BOERZK=\K
M18]5TXFPM-]@J:@J[M/7;?E6_P!G^VHUDV*A]9(MH0SV0:R;%HHN4%?A7%PD
M40,JDF4P#D?/EQ'MV1X<U0YA;GESX>T,>Y;1<*E,(N4W]7M_ET:1_P`9>N/^
M&FWLAWT'P_U!7Z?Z_;FLC=A_[VFJ/7_ZS^NGI_[M;;]>?WYO[H7_`+RZ?RI/
M^J8N;_\`D,/_`$;48?\`?J,?\$K!4K.B5S`F$3")A$PBR/U2_O\`/7/_`'==
M@?ZCK_-%=<O_`)U!_-F?)BZ,_P"/7^\NG\N1\YBA!^DD_L[R8_XJ4_W?]A/_
M`&%^X,YM;D>\?+AV+J&=]7@.WASX_9DI%T.T06B_U16Z(S:9$HU;M/TQJ,%H
MJ;E"$08R$]`RC6;E8F(?NR@F>3.PJSML**)@4,HX(GP(J`!JN)AR&'OB?DI,
M7RPX?AP[N,3RBNH[(5E<Z.Y-R_J,=<([/O+;3_C3;:GHY+?9FLS/;9V.UETZ
M'7TWTDW?2J'\OILTI3\F:@95,%0)\HB4#<>N2X_J@>WW?%7(2\81C##[8K7U
MV2[N[S\A'Z:W?W9;?]/IU-M=BVM%04`TH;>6;5J7I%?VA0T(&P,@F7+MXK^9
M++.0$_N`I@3#@`]<ED=8B("*N-;HGZ1EP[H*>7D(ZDV;LEX7NM.QM2D.T[&=
M0=-=>.T.CYMF4Y91"9UAKZLS=BB6QT"&<N`D*XV7<)-2\E</V;8!`>`RF)AA
MG[?9%4-<&S(F$(G/+Q^WLBL2=]?*>[['>(#KT?K@Y<->R7DP7K/7BE5N&65<
MS]-LLB]:PN[UA3:KE="-)*DZ0<`8H@=NHH/H(9/[.,1AQ\>$8<>]2UFF9^\P
M#<2O#R^ZG_Y$?"CHGI+J.>-1:;9;KHCKKL*UL55T%U:Q9;/'*[%56?-A;KF;
MVMXHX16.<?D,W6`@B.0[+W#V]LLD9!Q<[\?#'C\\%T<]>M`:FZPZ@HFD]*5*
M&I^OZ'78R!AF$0Q9M#/4V+8B:LQ*KLT4?S.:EU_>Y=NE.5%W"ISB/)LDDDXJ
MT7%QB<U1+CU0ZYW_`';KGL=<-/T>>W?J9M)M=?[(>PC0]GKJ4L7VN1;2!2%5
M541*93X#*"<S?YE?C]OR&YI@"=1^I3J.G3PC%<__`%AH-7[9?J"^^.R]\IQE
MVE>F5$HU`Z\TB<(9]%4MI**ME7M\C(-]\S()-P9T=(7)2!PY$%2\*%`P,W`G
M.!]WMS5XP;)$,S[$CER^"Z0MJ:GUSNS7MIU5M6GP-WU_<X1]7['6+!'MI"+?
MQ<@V4:KI&0<)J$24*DH(IJ%`#I&`#%$!`!R<\%\_=FN='P%6B7U3UP\C'7`E
MJ=VW6?2_MUNO5.F)]5ZM)H)T]",2EFD>Q?*<$6;!,NSN2`3V@0KL`]H!QGJ6
M.C-=>::C`B)E0QOAJ&KQSBO,W)6"@LE77$@&72S'8"'FTG_JAG\E(?6FK3W[
M2&\+L5L*TS6W4&]9&*B*JRA4E#2TP@@/`F,*S<X@/'].=9[@W%_1=WV>TZH4
MD]LQKL8#'R,)[B(KC+;>V?Z[LJ]WG3&LIW2W-PQP\\P#O!7Q:MS/;EHC5^GV
MQG+B5A)Z2+(D3(<RCMFD<I*VD!P,(N15/)K_`(./PB@3]V5V[:LFU;QN&Z)F
MEM/-DMTDY-<?XI[(:6X\=15%SW?/O&R+;M*67.JI,]X>.+F@_N1VQUNPX:0L
M@W^F)Z"W]I+X""W*G$Z]>R+A%/XP6>?,2"GUP$."&.HHBL80YY$!]?MYSP['
M=7;TV5=_4B29M2UH/!L/4ECN`+1WA>_?K.S8N^[-Z8@T2:5SR.+H^E-/>2''
MN*R!W>.13?FI5""`E485TY1`1$1*>UH&*(E'T+R4?3C/%Z1@MV=<VNC$/F</
M_"<CQ\5[O6<M=O>TN;"!ERCG_P"<9\EY=^&@R6W]>1H*#R]@D&GM]H\$!U,@
MD)BCSZB8!_=QQE?1F;Z&V*Z>1]$XN]S(JWURE?F-VT%/'ZY`;W1F06<>UFE=
M:5#KJY4K]5BHY]4583\JED&R*4LH91PBQ="\?D(#AX+Y-43K`<P@<Y0,/J4,
MQ#IQNN_W+?#6UM1-F2:KU-;"26#`N$&G!H:1!L,@8<5FW4_9VW;7L!SJ&FE2
MI](9>AX`#SB&.U.`B[4#%T<R(\%0ND&HJ!/:JE+18JS$STI.S,I&*+RS-!X+
M:/8F%H#5G\Q3"W(J/)SB7@PF^_TS[.K>Y[S1[DEVZAJ)LF1(E,?!CBV+G>:)
MAG#(+X>C&T['6[7F7.X4TJ?43YSV1>T.@QITP;'*.9XQ6(.HT>2M=H+U!L#"
M1C'MK>R11()BD%FT?+*,VYR\B)RMRE(`<\^I><R?J9/-?T]HZR=C.>Z2XGCJ
M+0''QQ]ZQ+I33BV]2ZZBD$B1+;/:`/U6N):.V&'N6"(VQ6V8WI<K>WU\AMB=
M0FYYZ,!,H2$@T9)I28M6CI9JT61541BTP(BD0_*9>2^G(!F7U%!;:;9U):YM
M<ZVT9DRV^I++6N<=$7-!((!>8N<1B<<8$K"J6XW6JWO67:7;VW2N$Z:[TI@>
M]K`'Z6NTM()#!!K0<!AA$!7WMMSMS;K!HW?]:8^L2;%=)1"P5>OS#23%J0IR
MJ1[@%'!V[EFK[@$`.413,')1`1'/)VTS;.V9SGR;^^HIW@@RYLQCF1X.&$0X
M=AQXKVMU3-U[KD,9/V[+IJEC@1-DRIC7Z1FPQ,"T]HPX06?+C$24ATG0D-@U
MH4+K4D$(*.?3K$OY\SCTY9JF0Z;A<IG"(.4!`H\&X,4H<YAEKJJ>1U8,BR5&
MJTU+C,<V6[]VYQ8[,#`P./82LYNU)43^C39]]IM-XI6B4UTQO[UK0\`0)Q$1
MAVP5,U77X)#I1?+*E%1[>P.6%BCG$XDS1"478B]C3_1*O``%SMCG2+^$3>T!
M`!X],O[CK:Q_5BCH'3'FB;,E.$LN.@.TN\P;E'$XKYMKT%"SHY77%LJ6VO<R
M:TS`T:RW4SREV<,!ADK(U78I*L=*=L/HE55F]=VK\L!VF)O>5%^UBD7!DA*(
M"E[D`,F(_O']N>ON.AD7#JQ;9-2`Z4VGUP/$M+R`>>,"O(VQ<*BV=&[I.I26
MSGU.@$<`X,!(Y81"S)TET=K>;UL>^V.#B;3.2TI)QP$EFR4@VB6C!4$0;HM7
M!3ID<K\^Y0XA[A`0X'C,5ZL[NOU)?_Z/0SIE/1RI;'>0EI>YPC$D9@<!P67=
M&]F;=J]N?UROD2JJNFS7M_>`/$MK3"`!&#CFXYE2M9]:]+Q]U0OC&D1;2::@
MF9J@W3!&(;.TC>].10B4P*S2D2&]05`ON`0Y^WUS7$W?>ZY]J=9IU9,=1NB'
M1Q>0<VE_U%O]V,%M"3T\V?3WAM\D44IE<R!;#!@<,G"7](=''5",5#3MUI>_
MLMH-=Z4Z"2N,<1&(4EH=1@$N$>Y@VA&9#NX@Y3@\BW+=$HC[0,8JHB/'V#FU
M.FFZ[),V\[9]UG&DGDO#)@=HU"82Z`?^%X).<`1Q6H.JNSK]*W*W>MGD"LD`
M,+Y9;ZFDRVAHC+/U,(`C#$'@L@]1MMZIM]BL$='Z^B=>;.EF_P!;+)1B(DC9
ME)@`%=!#D6Y7C`1,/O6:_8)N3B(CZ!XG4S;>Y+712)\^MF5VWI9TL+CYI9=E
MKA@^.37^"]_I3NG:]WKJB1(H95OW-,;JF!@@V8&_5Z<<60S<SQ4_\TPMZ)A%
MS);$_P#ZFNN7^`W<?]2B,',=Q^:NCZ#^S_U+#W5KKYKC;GZFOR![)O\``QUD
MD=$:FH=FUZSE&B+QI$V^Q0=)K*EB!!P15`[MC!R+DB`B7W)*J%4*(&(`Y)&#
M7=_Q@I=_";XK;%YT]:5?:'BC[FQ%FC&#[\CU6O;X-V[9HN7,-.U>:B)=C(Q:
MRA#*L7H@U,@*J0E/\*QR\^TP@,0B".$/EC]BH88&)R@8^`6F/R.;1O&Q?$/X
MB]*6"Z/Z[5.Z%PZNZTWO;TWJ[%=W2'$!!O96$>2A1$6[6S',5L?W#_$-[0]<
M#5IBW.$>_LYJZP`S"XX`##(#'+L\%U?ZAU%KK0^MZ?J75%5B:90J+`QM=KD#
M#,V[-LUCXMJFU1.M\":?U3U<J?O77/RHLJ8QSB)C".%\YQ,58\KU6Z\36_*K
MVADM1TMQOVE5^9K%;VA^3-DK3'0\\3X9)N#]$J9W!U6QE$BJ*^\Z:2RA"B`'
M$,=O%3$PT\/;V\`I`X4)A%RF_J]O\NC2/^,O7'_#3;V0[Z#X?Z@K]/\`7[<U
M?'9V280/;;0Y9QVC#EMGC@T7#UA62-]$WGIB!V;LJ2FHJ+=.`3;NY.-CY9JN
MJ@4WRE27(;V\&#-Z]$:VCI[E7T]1-8R?.ERM#7$`OTN>3IB<2(B([5SUU^H*
MRJM-OJJ:3,F2)$Z<9CFM)#`]LL-U0RB08=R\!`0]!]!_?G2:Y53(1,(F$0`$
M?0/4?V!DHKXZ@RL=+^0O1\1$O$)22K&L-XO;,TCC_6'KK66;TAO%*S9FX*)Q
MGYFNS6(@54Q3*"D?@/PCF@.M];1S9%'12YK'5;'O+F`@N:"&0)'".,(YP72W
M_'^AK9+KA73I,QE'-9*:QY:0UY:9FH-)S(B(PYA0O_22?V?Y,@^\.U*?/WC_
M`*B?^T?O'.=F@@&/,?+YKIB<#$'@0(</AP^W-;K/*_XM:_Y%=?TFP4R[/-*]
MK]"2JUMZZ;RB%7+1S6;`*K1TI"V%:/24DEZS)N8]$YA1Y6:KIE63*80$AG.&
M</;XJACRPX91RY\,?`E:Z:IY!?.AU-@4-;=JO%]9.VTY74B1L=NOJQ+?S*6[
MM4`(FRE9ZN1;=\VBWJ[1,#KG!4BIUC#\B*9N0QB/JRAP^.'Q'@,U7IE%\02&
M$X91_L[3W*P]T,?--YD(@G7N>Z]E\9O3&T/V"&Z[5>K$NOOR_5`BI%I.G15=
M320>Q"<B0HE'XTS-EA`OS+D`/:,C$1R:??XC@I;Z<MP?$D`G#[^SXJ=ODTZ!
MRR/AJM/1?ICK9S8'-3KNK*OKZDQJC=&0E&E8NM?E)B1<+K&315D7B;9P]<G$
M0]ZIS<?<&5!T'!QC`*F6X>I$X`E;5NK].FJ7U@Z^T&Y17Y?8:KHS5U2M,([!
M)?Z*8A:)"1$U%N0_&BM].\;*)'#U*;@?M#*5;)!)/`KD9\/?0VG6_P`P?;_9
M]$M$K;.GO0?<FR(+KE".%!=5"!VYM%TZ?6)K53"4[<XU)@Y7.9VEP#L7A#_=
MQ@.B<(%H$!V<3#Y=ROO=!FD_5[1]V7%=2G?_`*4Z\\@G5C9'6+8[UY"1]R;,
M)"NVR,335EJ7=JX_0FJE:XXBG`*+P\TT24,G[B_*F!B"(<Y!CPS'P5EA#7`G
M+X^"TQ:8[3^:;HK58OKIV(\?UC[NQFNHC^6==]B^N=H9OWUZKD*T!C67%X@Y
M0Q5(J13:H(IKK+&(\6`#'.E[^!,B?Q#MP\</L^)5TB6\DQ#<8?>3]W./!2'Z
MHR_F1[5=KJ9O_L36J]T3ZA:]BYINSZS(23&[;'W6^F&XH-WFPE#I$5JX1!BD
M43#E`R"A1!(JQ3F,60<>S'YX%6_(V(A$D>&>!';#/DK4[\=$^W^H^Y,1Y1_&
M2TI]HW0XIB.ONR76ZZ2QZ_7M_P!&C3J.F+J*DBE3:M+8P`H`4RA_E,H4BB)5
M%`]@O-J!&.0/=W_%2'Q;H=#2!AWQ]@L2WCOGYQ>R%4<:6T'XO9KK%LRXQSB"
MFM[;LN2#>B:W0=(&:RUDJIE&[,)V38E.=1@"OM.8P%.5)0_M(+C#A[?`^_Q@
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MK0JO8I&5:2ISD40D$(I5PO7DR@`\G!RJ1#Y.0#\/N^_-G;IZE6:LV9,E4$]K
MKS4R&L<P1!:7@";[AJAX+4^T>E=[HM]2YMQIW-L=+4/>UY@0\,),H>)TQCVK
M.G=S35]V(]H$]KV`<3DC%)RK.0%H<A5V2:9VSN,5X.8H&*9PHIQQ]@E]?NS$
M.DNZK-8Y5;1WN<V53S-#FQC!QQ#Q[@/>LUZS;1OE_G4%=8)#IU3*#VNTPBT"
M#F'WD^Y69V-T_M2_["TY8X*H2+]M#UVJIV!0@IE)&OFLRU=OD#B<Q5#&03(8
MQN0Y],]38FZ-N66S76AK*EC'S9\TR\_.TRR&GEB<,%Y/4/:>Y[[?+/<**EF3
M)<FGDB;EY'"8USASP$28JX.VNGMC;`VSKZ=JE;>S,-%,F:4B[:B0A69R2Y'"
MGN,80$1^$/=Z<\<9\?37=%BLNVZZCN4]LJJFO)8TXZO(0/BOMZI[2W#?=U4%
M=:Z=\ZCE,:'N;^&$R)^&*DAVEJ-BO&D[16JM&.)>;?J1(M&#;V?(L#>1;+K<
MB<0`I2))B(C]OIF!]/;G0VC=M-<+B]LND9KBXQ@(L<!EVF&."V)U*M5PO.S*
MJW6R6Z;6OT:6B$3![2<^P1PQ5`Z?T:TZ]U"C7[A$.829+/S3L[)S[!."#ET)
MT%`$@B`E4)ZY]O4Z\6^^;G=6VR8V;2>C+:'".8;B,>17P=)[)<K!M)M#=I3I
M-9Z\UQ:89%V!PYA8+T%IW8U6[+7>Z6"LO(VLR)[,9A*+>P477USHYFP$`HB)
M?D(/(<\9F&\]T6*X["I+315#9E?+$K4P9C2,?<L(V+M+<-LZC5MYKZ9\NW3#
M.TO.1U.P]ZH>U^N.WM<;1D-N]>U5'"<JX<2#Z%;KD!^S=/S?)*M#,E3$+,1+
M]URJ"8<G3$W''!2FSZMM;[VS?-OLVOO9H;Z;0QDP@Z7-:(,.H?PWM&$<CWDA
M?+NGI[NO;^Y9F[=A.+O5<7OE@C4USC%XTG"8Q[O-I&(,<(`%4UJIWSV=8H=%
MT+G7+5@JFJN_*P)7H<J8CP==ZU6.\<2R@$.(?"3GD!_T?3G/IF,Z-[?HILR7
M"OFO!`;J]5_<TC2&##,^]?-+?UPW)7R9<R-NDL()?I$ID.;@2XO./TCW*7'8
MJFV^VZ$F:G%HGL]L<-81)3Z-$K89%VV=-3O'*2`G$J)#B0Q^.?0,UIL>ZVNV
M[RE7*H(I[:UTPC48Z6D'2">/`+:?4"T7:Z[&G6NF!J;JYDL'2-.MP(U$#AD2
ML.4#55^B.H%IU\^@736XOTYL&T*<`%PH+EPU,BF4?4@BLFF/`_8']&91>MQ6
M:JZG4]ZDSFNM;#+C,X"`,?<5B-AVQ?:3I/56&?(<V[S!,A+XG46P'C!>W6K1
M$LEH>[ZTVG`O(8+1-/!4:KF3%<C<[%@5L^;"`F*4Z#EN!@_:8O[\IW[O&F=O
M&DO^W9S9OY>4V!$81U.BT]X,.XJYTZV35-V/6;<W/(?)%3.=%IS@6M@X=Q$>
M\*.T=JSMQUSEYF+UDW<66LR+DRC=:.03F&+PI`'XGB\290B\:_!,?:?T`#&^
MSW!P.9Q/W%TSWU3RJG<!%/<9;8$.)8YL<VA^3VQQ'$#DL`I]L=5>GU5-IMM@
MU-LF.B"T"8UT,G&7$%CH8'($\UE_2=5[>639S.^[$GW]3KJ(I-Y>&D2HE2EH
MYHH<X1+&N<B+,%U#F-]482F+[A,!C<`7,7W;<NF=!8'66Q2&5-><63&Q\CG#
MZW3?Q0`AH$>`(&)66[-M75:X;D9?=PU#Z6WB`?+=#]XUI^ALK\(),=9@<R"<
ME5]^Q_;2#VJC=M8+*SM328),XJ"BTP=MT""4BCYM/09SD4>JKN$_>5<@@'M]
MI0$!`0SYMES^FU9MQUHW$T2;D7DOF/,"?U3+F9-`!@6GC$XB!7U;ZD=4J+<[
M;SMEQGVH2PUDM@B&_K"9+)!<21$.!R@(@Q5K=9-#[4+M^5W?M.*0K*RY9=PE
M&%208KO9283(FX5+%H"(1K%JF`B4IN/<;]OJ.>AU`WCMQVV)>T=NS'5#&E@+
M\7!K&8@:S];B<R,EYG3?9&Z&[LF[TW-*;3O<)A#,&ESY@@3H'T-`RCGVK*FL
M]N[&V;V0O497W;0^GJ>@>(?BJT^0JDBQ!5!-2.=%,'MD'LJH<%.1,46J'(``
MAZX[N#;5BL&Q*.?6-<-T51$QL#^!T"=0_5:R$..MRR?;>ZMP[CZAUU-0N:=H
MT8,MQ+?QMB!H=^NY\8YC0WFIK9JE;A6ABZ]4]^R?Z@O2';ACKV27Z\UCJ!L[
M7DYL<JS8(MA<)QK&IQ<*HB*GU(N'1T#`40+[?3[<DB,#R'VJZ(>F3AE#MSBO
M[>H?5??6O?-;Y'.S%PU_(PVD-R:HUG`ZVO:Z[8["SRT-_)WYFS:HD4%PF=I^
M6K>X3E`/P9)(+0WB(_%'.!E-;QB5._R;ZMOF[>@/;#4VKZ^YM>P;]IVQUVI5
MQF=--U,3+SZ?Z9B@=4Q4RJ*^P>.1`/3(''N/R*H;B8<P1[P0H5VGQC'[=^'G
MKWTPW(M):EW#KS3FH9*JV9N"3B6U3O+6\`T4@9-442J"X;1DTE\;HB0\F)^(
MO)B%`8&#8*0\M=J;\5&/5?=7S5]1ZI':,[/>-VV=O;/2HA6$K?8;K?;(V8A]
MDQT4@#""G;A'O!!2!EGWQ)G=`H8KM0@F4.B53DHA`8&,,/;P5PME.\P,(Y]G
M/]"DCTJ1\PG87M2U[.]O4*ET_P"K\#39BO5#IM799O=K3=Y"6#AC;MB2_P`!
M!A92+4**PE,9%=(X$131,B8ZH0,1$Q!CEX>P5$96GRQ+N>6&'#OR[%?VX]V^
M4^%\J6C-0:MT34IKQUS]?;NMK[;<PRKJ;BG/Y)(N)5S_`#1^<MV\)(Q\\1NV
M;1PM%CO$3"H!@^ZJ&"B#-!,3KCE]JW&9"H6L3RR^-6L>4KJ\CU_GMB36KY>L
MWN+VC1K7%,&LLS;W*"@;)`QS:Q1+@R"LA`.&MF7!8B"Z"Y3@0Y3#[1*9`$0.
M7M[?I5;'Z#$B(]LN17+'<^ROD3\5,5'=7?+[UK9]\>BA))G%TG>C#YIR=I\:
MSX;Q\M4=E(MVLO"V&.17`&C><&,ERJ%,1J_!(H&RILU\L^H"0X',9YX9>$,(
MQBJWLESI>@")(((('F'&(Q![>?+@M@6EV=2WY0E=P^-G>"'<K3[8BKVS==M@
MS496.V&G4#&2#\JB7$VK&M;LPCSF%%!"9%L=4"B*<R^-P4=O[6ZM7>SZ:2]1
MK*`0@Z/[QHX0=^(#DX1X:EI/>?1>R7G55V33074XZ0/W+X\"W-A[6X<VJLTS
M8]6O*LK'Q2\A&V6NK?2VJCVF(D:K?*D[^59`&]EJ$ZW8SD4"RB!_@6.C],[(
M7Y$%%4A*<>B;'N2S;CI_S%HGMF"&+<GM_:8<1WY'@2N7]Q;4ONUJG\M>I#I<
M3Y7C&6^'ZKQ@>[!PX@*^\]Q8ZK+NFP:GK]FT<V:3,@YE'`,8&"CF3V<M-GDC
M\`G%U:K0[=]/V*24$P<(M&ZIP`>3`!>1SR;Q?;38*8U=VGLDRN`)\SNQK1YG
M>`PXP7M6/;UYW)6"BLU/,GSB0"0/*R/%[SY6CO(CPBJ?L:#+KK6YMU][MP,^
M@W719`[R#J(OXF:[9[@1;@HX/#Q%=8C-1U`;RK5$"B1L27E`37+\QHQ0HB'/
M6[.K]QN)=1[=!I:`B!FG^*[G#,,$.47<8A=-;-Z)6JU%E?N-PK*\0(E#^"T\
MB"-4PC/'2W`@M<%KWJ'=GNQWX//]5/!%U8=]6NNSIZ9EL;M?<`6C;W9E/<BT
M4LETVS*FEEFLT+83>]%LXG+$":@"F=,GX0TU-GS9TTSICG/F%V+G'5JP[<3V
MG&,8C**WO+IY-.ULEFELM@`:UH@T-'X6P$.6$`(1XKI`\-WB;B_%9I_8-<?;
M7E]O;0W;9HJ\[3L2[)*,KC>Q,(P[`&579G^:44:?QSF6<O%SK.E1%3V)`/LR
MUY0(#GG[88(]^LX"`X#DMQN0J$PB81,(L=[=@;Q:=6;$K&M+,SI6P+'3+'!4
MVY/V:\@UJ=BEXIU'Q=E.P;KM5GIX)TX*Z(D"B?R'2`!,`"(Y(S4@P,3DH>^,
MGH;`^.OJI5>O[.R(7RW_`)O8+GL[9!8D8=S?;[:Y1Q*S$TNT4=/G":"'SE;-
MBJ+*&(W1('.1V<![>Y2XQA```"&"V#85*81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$7R<A5"&(<H&(<IB'*8.0,4P"!BB'W@(#D@D&(S4$`B
M!Q!5IU"AU"A-Y)I4()G!-YB4<3,DFT!0?JI%T!06<',LHJ8H"!/PD*()DY'V
ME#D>?2N=XN=X?+F7.<^<^5+$MI=P:,AA#WG$\3@O+M5DM5D9,EVJ0R0R=-,Q
MX;'S/=F<2?`#`<`(E7=GF+U4PB81,(F$3")A$PB81,(K<MM/JM^KDM4+O7(6
MV5:>9KQ\S7[#&M):(DV3E,R*[9XP>I+-UTE$SB'!B^G/IA2"08C,+E8[F_IM
M/Y5V"IVG\1VWIKJ%OV%<.)MEKB/GI*+UY,R*AP4.VK4PDX4=4GZD!$@-SE<1
MA2&'^$7G(/ZP^J/VY?9W*XU\0&3(EO/,Q^[L6OHWD]6B+["=8O/7UGN?7[L+
M5&IXO7_>C5$2>M6]J10RB+&8DCUQ`(VR5MT*:*CA1FHNS5:)^YTU]RG&?=07
M&KMU6VJH9CI,YI!#FDMR/9W?$+X[E;:&[4CJ2MDLGT<P8RWM#H1RP/'/$+9U
M':/W'+TUI>Z9VEZN6SJ6^A%+`'>J3L,;'+0-;3:*+BTE]6)'2AGVQ#(%!1(X
M+(1_O$"JL_=^$=M2^M&X6VPTCI,EURA`3H<.99])=\.8BM,3^A&V)MY_.,G3
MY=JS-.#&+HC`3#Y@P\?Q#@8+6I,^4+6E"V<]T%X8=#7'O5W1LX*UF?[H;.A7
M=F,R45<_&Z4H$4_;IQ<%56;E(KAF008PJ)#&*"1^`'-4W2[W"\51K+G.?/JH
M9DQ@#E`9`=@P`6XK59;99:-E';94NFHQDUH@>\\7$\SC'$J9/5#].GM/L1L)
MEVN\T&\K+V"VK*JI2Q=%L;$Y=5&#'D%F<98["U61*Y9L`X(6-C$VS(J7*1Q.
M`9YQQ,3F".[#["<5Z/JEN#,(81XD?IY?8NKS6NL-=Z;I<%KG55*K>OJ+6&2,
M=`52J132&A8MD@4")(-63---,H%*'J8>3&^\1PK2OO")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3"*"G?FC^/K8^H7%-\A4MUY@]8S9%VL=+[ZO5*UN2/>&,B`N
MZI<+5-0#J)DT'`HF]S1R7W'`@*%.7\(N&.7]GZ%4S4'19&/8N0:7\%_C@>7I
M[8*5YJM'0_C=7L2<K;=>F[/:QD2,[:F].9"I&M:&QDM:.#N&W(?F;M-.424'
M@K8X%`1@@\_+#'[.['&/.`5WU#!V'F@!E^'M[>176%XX]7>,[3NLUJ)XY[+U
MRN%:B0`EHL>E]FT/;5CEGP`@FN\NEPJLY//W+M=5,AC)JJ)H$4'^&D3GC)X]
MJM.UQBZ,>U;(L*E,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
C)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
